DolPHIN-1 study group: Randomised controlled triak of dolutegravir (DTG)- Versus efavirenz(EFV) – based therapy in mothers initiating antiretroviral treatment in late pregnancy -

Home
Who We Are
- - - We’re a national non-profit dedicated to protecting African communities from infectious diseases. Our work strengthens health systems to withstand current and future health challenges.
What We Do
- - - We reimagine healthcare by translating bold ideas into real-world impact. Our work encompasses building strong health systems and improving health outcomes through prevention, diagnosis, treatment, and emergency response.
  - - Sub-programmes
    - Kasangati
    - Academy
    - African Centre of Excellence
Where We Work
- - - We operate in 92% of Uganda's districts, with strategic partnerships in 23 African countries and nine others worldwide. Through these collaborations, we gain diverse insights to develop tailored solutions for local communities.
  - - Where We Work
Impact
- - - Everything we do has just one goal: a healthy Africa free from the burden of infectious diseases. We work with communities and partners to address complex health challenges, ensuring improved health outcomes.
  - - Impact
    - Projects
Resources
- - - We rely on evidence and our expertise to deliver established interventions to improve access to and demand for healthcare services and overall quality of care.
  - - News & Media
    - News & Events
    - Stories
  - - Publications
    - Reports & Strategic Documents
    - Peer-Reviewed Articles
  - - Community Info
    - Requests for Applications (RFAs)
  - - Data Tools
Contact Us
Search for:

DolPHIN-1 study group: Randomised controlled triak of dolutegravir (DTG)- Versus efavirenz(EFV) – based therapy in mothers initiating antiretroviral treatment in late pregnancy